Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Apr 20;7:992. doi: 10.1038/s41598-017-01019-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2017

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Electrophysiological evaluation of IgG4Δhinge-637 treated rhesus monkeys. (a) Treatment schedule. Monkeys were treated with PBS or IgG4Δhinge-637 (IgG4Δhinge) on three consecutive days (T1-T3), 6 hours prior to challenge (Ch1-Ch3) with PBS or IgG1-637 (IgG1). Intercostal muscle biopsies, single fiber electromyography (SFMG) and compound muscle action potential (CMAP) measurements during repetitive nerve stimulation were performed before (pre) and 7 days after start of treatment. Red arrowheads indicate blood sampling. Mean consecutive difference (MCD) of the delay between motor nerve stimulation and muscle fiber action potential (Jitter) (b) and neuromuscular transmission failures (Blockings) (c) in the orbicularis oculi muscle in different treatment groups. Decrement amplitude (d) and area (e) in the CMAP of the extensor digitorum brevis muscle in different treatment groups. Reference values were recorded before start of treatment (Pre). Data represent mean ± SEM.